BR112023021886A8 - Polipeptídeo de fusão biespecífico multifuncional - Google Patents

Polipeptídeo de fusão biespecífico multifuncional

Info

Publication number
BR112023021886A8
BR112023021886A8 BR112023021886A BR112023021886A BR112023021886A8 BR 112023021886 A8 BR112023021886 A8 BR 112023021886A8 BR 112023021886 A BR112023021886 A BR 112023021886A BR 112023021886 A BR112023021886 A BR 112023021886A BR 112023021886 A8 BR112023021886 A8 BR 112023021886A8
Authority
BR
Brazil
Prior art keywords
conjugated fragment
fusion polypeptide
bispecific fusion
terminus
conjugated
Prior art date
Application number
BR112023021886A
Other languages
English (en)
Other versions
BR112023021886A2 (pt
Inventor
Di Lu
Lisheng Lu
Yongting Huo
Original Assignee
Guangdong Fapon Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Fapon Biopharma Inc filed Critical Guangdong Fapon Biopharma Inc
Publication of BR112023021886A2 publication Critical patent/BR112023021886A2/pt
Publication of BR112023021886A8 publication Critical patent/BR112023021886A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

polipeptídeo de fusão biespecífico multifuncional. o presente pedido está relacionado ao campo técnico de biomedicinas e, particularmente, a um polipeptídeo de fusão biespecífico. o polipeptídeo de fusão biespecífico compreende uma fração de ligação ao antígeno. a fração de ligação ao antígeno compreende uma primeira fração de ligação ao antígeno compreendendo um primeiro polipeptídeo compreendendo um primeiro domínio variável de cadeia pesada vh1 de um primeiro anticorpo a partir do n terminal ao c terminal, o qual está operacionalmente ligado a um primeiro fragmento conjugado; e um segundo polipeptídeo compreendendo um primeiro domínio variável de cadeia leve vl1 do primeiro anticorpo a partir do n terminal ao c terminal, o qual está operacionalmente ligado a um segundo fragmento conjugado, em que o primeiro fragmento conjugado e o segundo fragmento conjugado são capazes de se ligar especificamente; e o primeiro fragmento conjugado é um receptor e o segundo fragmento conjugado é um ligante; ou o primeiro fragmento conjugado é um ligante e o segundo fragmento conjugado é um receptor.
BR112023021886A 2021-04-22 2022-04-21 Polipeptídeo de fusão biespecífico multifuncional BR112023021886A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110436970 2021-04-22
CN202110871320 2021-07-30
CN202111121937 2021-09-24
CN202210240917 2022-03-10
PCT/CN2022/088198 WO2022223001A1 (zh) 2021-04-22 2022-04-21 双特异性多功能融合多肽

Publications (2)

Publication Number Publication Date
BR112023021886A2 BR112023021886A2 (pt) 2023-12-19
BR112023021886A8 true BR112023021886A8 (pt) 2024-01-09

Family

ID=83723420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021886A BR112023021886A8 (pt) 2021-04-22 2022-04-21 Polipeptídeo de fusão biespecífico multifuncional

Country Status (10)

Country Link
EP (1) EP4317184A1 (pt)
JP (1) JP2024514802A (pt)
KR (1) KR20230160389A (pt)
CN (1) CN115925967A (pt)
AU (1) AU2022261268A1 (pt)
BR (1) BR112023021886A8 (pt)
CA (1) CA3217520A1 (pt)
IL (1) IL307899A (pt)
TW (1) TW202241968A (pt)
WO (1) WO2022223001A1 (pt)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1570267B1 (en) 2002-12-03 2011-10-12 UCB Pharma, S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP3936521A1 (en) 2013-03-15 2022-01-12 Xencor, Inc. Heterodimeric proteins
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
CA2935599A1 (en) * 2014-01-08 2015-07-16 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterodimeric protein and uses thereof
CN106459219B (zh) * 2014-12-19 2019-01-08 江苏恒瑞医药股份有限公司 白细胞介素15蛋白复合物及其用途
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
WO2017205726A1 (en) * 2016-05-27 2017-11-30 Altor Bioscience Corporation Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
BR112020005676A2 (pt) * 2017-09-22 2020-10-20 WuXi Biologics Ireland Limited novos complexos polipeptídicos biespecíficos
KR20210003813A (ko) * 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
EP3781599A1 (en) * 2018-04-18 2021-02-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof

Also Published As

Publication number Publication date
AU2022261268A1 (en) 2023-11-16
IL307899A (en) 2023-12-01
JP2024514802A (ja) 2024-04-03
TW202241968A (zh) 2022-11-01
BR112023021886A2 (pt) 2023-12-19
EP4317184A1 (en) 2024-02-07
KR20230160389A (ko) 2023-11-23
WO2022223001A1 (zh) 2022-10-27
CA3217520A1 (en) 2022-10-27
CN115925967A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
RU2011148918A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
AR112419A1 (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
AR077111A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
RU2011148913A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
EA201200526A1 (ru) Поливалентные антитела, стабилизированные дисульфидом
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
EA202091364A1 (ru) Анти-pd-l1/анти-cd47 биспецифическое антитело с подобной природному антителу структурой и в форме гетеродимера и способ его получения
PE20110926A1 (es) Anticuerpos biespecificos anti-egfr/anti-igf-1r
NZ707327A (en) Mice that make binding proteins comprising vl domains
HRP20141032T1 (hr) Bispecifiäśna agonistiäśka protutijela receptora smrtnosti
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
RU2010133547A (ru) Анти-cldn антитела
EA201100527A1 (ru) Биологические продукты
PE20120540A1 (es) Anticuerpos triespecificos o tetraespecificos
PE20221282A1 (es) Anticuerpos que se unen a hla-a2/mage-a4
MX2014001799A (es) Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.
PE20091172A1 (es) Anticuerpos bivalentes biespecificos
BR112021014522A2 (pt) Molécula de anticorpo biespecífico e anticorpo biespecífico que se liga simultaneamente a pd-l1 e lag-3
EA201200725A1 (ru) Поливалентные антитела
BR112012019887A2 (pt) camundongo da cadeia leve comum
AU2010234031A8 (en) Trivalent, bispecific antibodies
FI3402821T3 (fi) PSMA-sitova vasta-aine ja sen käyttöjä
MX2020013606A (es) Constructos de anticuerpos multiespecificos.